Xianbo Biotech (先博生物) focuses on developing advanced immuno-cell therapies. The company is working on globally competitive universal CAR-NK products and next-generation mRNA in vivo cell therapy candidates. It is also actively advancing clinical research and regulatory filings for CAR-T programs targeting solid tumors. Xianbo aims to deliver effective, safe, and accessible cell therapy drugs for patients with hematologic malignancies and solid tumors. Recently the company completed a ¥200 million A+ financing round. That financing round was led by Youshan Capital, with participation from Yuanhe Origin, Pudao Capital and Guochuang Qinzhi; Haoyue Capital served as financial advisor.

Total raised

$28M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2024